Therapeutic charisma of imidazo [2,1-b] [1,3,4]-thiadiazole analogues: a patent review

Pharm Pat Anal. 2023 Jul;12(4):177-191. doi: 10.4155/ppa-2023-0006. Epub 2023 Sep 6.

Abstract

Imidazothiadiazole was discovered around the 1950s era, containing an imidazole ring fused to a thiadiazole ring. Imidazothiadiazole exhibit versatile pharmacological properties including anticonvulsant, cardiotonic, anti-inflammatory, diuretic, antifungal, antibacterial and anticancer. Despite of the being discovered in 1950s, the imidazothiadiazole derivatives are unable to being processed to clinical trials because of lack of bioavailability, efficacy and cytotoxicity. The recent patent literature focused on structural modification of imidazothiadiazole core to overcome these problems. This review limelight a disease-centric perspective on patented imidazothiadiazole from 2015-2023 and to understand their mechanism of action in related diseases. The relevant granted patent applications were located using patent databases, Google Patents, USPTO, EPO, WIPO, Espacenet and Lens.

Keywords: antagonist; derivatives; imidazothiadiazole; lead; pharmacological properties; potency.

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents
  • Thiadiazoles* / chemistry
  • Thiadiazoles* / pharmacology

Substances

  • Thiadiazoles
  • imidazothiadiazole
  • Anti-Inflammatory Agents